Tyra Bioscience (TYRA)
NASDAQ:TYRA
Want to see TYRA full AI Analyst Report?
Top Page
Tyra Bioscience
(NASDAQ:TYRA)
Select Model
Select Model
Rating:51Neutral
Price Target:
$33.00
▼(-7.20% Downside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and elevated cash burn), partially offset by a strong, low-debt balance sheet. Technicals are moderately supportive with the stock trading above key moving averages, while valuation signals remain unfavorable due to negative earnings. Recent corporate actions modestly improve the outlook via added capital and strengthened governance, though dilution risk remains.
Positive Factors
Proprietary SNÅP platform & FGFR focus
Tyra's SNÅP platform systematically profiles FGFR mutations to inform targeted drug design. This platform-driven approach is a durable competitive advantage: it can produce multiple program leads, accelerate rational design against resistance, and support sustainable pipeline expansion across FGFR-driven cancers.
Negative Factors
Pre-revenue with heavy cash burn
Tyra is still pre-revenue with substantial, rising operating cash outflows (~$(102)M TTM). Persistent negative cash generation is a structural constraint: it requires ongoing financing, elevates dilution risk, and forces prioritization of programs, making long-term progress contingent on capital availability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary SNÅP platform & FGFR focus
Tyra's SNÅP platform systematically profiles FGFR mutations to inform targeted drug design. This platform-driven approach is a durable competitive advantage: it can produce multiple program leads, accelerate rational design against resistance, and support sustainable pipeline expansion across FGFR-driven cancers.
Read all positive factors
Tyra Bioscience (TYRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.93B
Dividend YieldN/A
Average Volume (3M)370.94K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue GrowthN/A
EPS Growth-33.07%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.18
Shares Outstanding59,470,383
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.52K
Enterprise Value/Ebitda-14.29
Forecast
1Y Price Target
$49.78Price Target Upside39.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.58
Revenue Forecast (FY)N/A
Tyra Bioscience Business Overview & Revenue Model
Company Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fib...
How the Company Makes Money
Tyra Biosciences does not primarily generate revenue from product sales because it is a clinical-stage company without approved commercial products. Its earnings have historically depended on external financing and, where applicable, collaboration...
Tyra Bioscience Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -410.00K | -546.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -129.55M | -119.40M | -103.66M | -79.59M | -58.63M | -26.15M |
| Net Income | -131.10M | -119.95M | -86.48M | -69.13M | -55.33M | -26.29M |
Balance Sheet | ||||||
| Total Assets | 412.04M | 282.61M | 363.56M | 225.86M | 266.18M | 306.70M |
| Cash, Cash Equivalents and Short-Term Investments | 383.47M | 256.00M | 341.44M | 203.47M | 251.21M | 302.18M |
| Total Debt | 5.70M | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M |
| Total Liabilities | 24.46M | 23.43M | 20.41M | 21.59M | 8.35M | 4.96M |
| Stockholders Equity | 387.57M | 259.18M | 343.15M | 204.26M | 257.83M | 301.74M |
Cash Flow | ||||||
| Free Cash Flow | -102.47M | -95.28M | -70.44M | -50.91M | -50.84M | -24.41M |
| Operating Cash Flow | -102.25M | -95.14M | -69.77M | -50.14M | -50.28M | -23.75M |
| Investing Cash Flow | -79.81M | 72.46M | -98.40M | -144.60M | -559.00K | -645.00K |
| Financing Cash Flow | 166.30M | 8.10M | 202.14M | 1.54M | 632.00K | 311.35M |
Tyra Bioscience Technical Analysis
Positive
35.56
Price Trends
35.86
Negative
33.49
Positive
24.71
Positive
Market Momentum
-0.54
Positive
44.99
Neutral
14.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TYRA, the sentiment is Positive. The current price of 35.56 is above the 20-day moving average (MA) of 34.41, below the 50-day MA of 35.86, and above the 200-day MA of 24.71, indicating a neutral trend. The MACD of -0.54 indicates Positive momentum. The RSI at 44.99 is Neutral, neither overbought nor oversold. The STOCH value of 14.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TYRA.
Tyra Bioscience Risk Analysis
Tyra Bioscience disclosed 87 risk factors in its most recent earnings report. Tyra Bioscience reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tyra Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $1.43B | -47.34 | -1057.44% | ― | ― | -13.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.93B | -15.04 | -42.66% | ― | ― | -33.07% | |
48 Neutral | $1.63B | -25.86 | -56.87% | ― | ― | ― | |
46 Neutral | $1.81B | -5.04 | -64.21% | ― | 27.23% | -12.53% | |
43 Neutral | $49.31M | -0.41 | 174.85% | ― | -55.42% | -248.85% |
* Healthcare Sector Average
TYRA
Tyra Bioscience
33.17
24.18
268.97%
KALV
KalVista Pharmaceuticals
26.79
15.39
135.00%
PVLA
Palvella Therapeutics
116.26
92.43
387.87%
GOSS
Gossamer Bio
0.22
-0.94
-81.29%
NRIX
Nurix Therapeutics
17.47
7.43
74.00%
Tyra Bioscience Corporate Events
Executive/Board Changes
Tyra Bioscience Expands Board, Appoints New Independent Director
Positive
Apr 17, 2026
On April 16, 2026, Tyra Biosciences’ board of directors expanded its size from nine to ten members and appointed industry veteran Habib J. Dable as a Class II director, with an initial term ending at the 2026 annual shareholder meeting. The ...
Executive/Board Changes
Tyra Bioscience Strengthens Financial Leadership with New Officer
Positive
Apr 2, 2026
On April 1, 2026, Tyra Biosciences, Inc. appointed Vice President of Finance Julia Rueb as its principal accounting officer, succeeding Chief Financial Officer Alan Fuhrman in that specific role while he remains the company’s principal finan...
Private Placements and FinancingRegulatory Filings and Compliance
Tyra Bioscience Raises $126 Million in Block Share Sale
Positive
Mar 4, 2026
On March 4, 2026, Tyra Biosciences, Inc. agreed to issue and sell 4,000,000 shares of its common stock to a large investment management firm at $31.50 per share, in a block transaction under its existing at-the-market equity offering program. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.